CN101610754A - 含有微粒油性混悬液的药物组合物 - Google Patents

含有微粒油性混悬液的药物组合物 Download PDF

Info

Publication number
CN101610754A
CN101610754A CNA2008800051218A CN200880005121A CN101610754A CN 101610754 A CN101610754 A CN 101610754A CN A2008800051218 A CNA2008800051218 A CN A2008800051218A CN 200880005121 A CN200880005121 A CN 200880005121A CN 101610754 A CN101610754 A CN 101610754A
Authority
CN
China
Prior art keywords
pharmaceutical composition
isoxazole
pyrimidinyl
acetamido
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2008800051218A
Other languages
English (en)
Chinese (zh)
Inventor
佐藤泰纪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
Original Assignee
Aska Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharmaceutical Co Ltd filed Critical Aska Pharmaceutical Co Ltd
Publication of CN101610754A publication Critical patent/CN101610754A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2008800051218A 2007-02-16 2008-02-15 含有微粒油性混悬液的药物组合物 Pending CN101610754A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP035916/2007 2007-02-16
JP2007035916 2007-02-16

Publications (1)

Publication Number Publication Date
CN101610754A true CN101610754A (zh) 2009-12-23

Family

ID=39689861

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2008800051218A Pending CN101610754A (zh) 2007-02-16 2008-02-15 含有微粒油性混悬液的药物组合物

Country Status (9)

Country Link
US (1) US8309138B2 (https=)
EP (1) EP2123255B1 (https=)
JP (2) JP4588791B2 (https=)
KR (1) KR101434706B1 (https=)
CN (1) CN101610754A (https=)
AU (1) AU2008215659B2 (https=)
CA (1) CA2677842C (https=)
ES (1) ES2423929T3 (https=)
WO (1) WO2008099615A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103655512A (zh) * 2013-12-12 2014-03-26 海南海力制药有限公司 一种硝酸芬替康唑阴道软胶囊及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
WO2019022152A1 (ja) 2017-07-26 2019-01-31 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用
WO2019036663A1 (en) * 2017-08-17 2019-02-21 University Of Delaware FURANE COMPOSITIONS AND METHODS OF MAKING THE SAME
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8546591A (en) * 1990-09-13 1992-04-15 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
JPH0616556A (ja) 1992-07-02 1994-01-25 Yoshitomi Pharmaceut Ind Ltd 難溶性薬物含有製剤
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
JPH07138151A (ja) 1993-11-15 1995-05-30 Kanebo Ltd ソフトカプセル剤及びその製造方法
BR9607035A (pt) 1995-02-13 1997-11-04 Searle & Co Isoxazois substituidos para o tratamento de inflamação
JPH1081621A (ja) 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
WO1998007414A1 (en) 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
AU754830C (en) 1997-05-22 2004-02-12 G.D. Searle Llc Substituted pyrazoles as p38 kinase inhibitors
CA2320087C (en) * 1998-02-09 2006-12-19 Joel Bolonick Treatment of chronic inflammatory disorders of the gastrointestinal tract
JPH11302156A (ja) 1998-04-16 1999-11-02 Tanabe Seiyaku Co Ltd ポリペプチドの微粒子化方法
JP4191825B2 (ja) 1998-09-10 2008-12-03 あすか製薬株式会社 ５−アミノイソキサゾール誘導体
PE20001227A1 (es) 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
JP2002533378A (ja) * 1998-12-23 2002-10-08 アムジエン・インコーポレーテツド タンパク質の徐放用ポリオール／油懸濁液
KR100711538B1 (ko) 1998-12-25 2007-04-27 아스카 세이야쿠 가부시키가이샤 아미노피라졸 유도체
WO2000040220A1 (en) * 1999-01-06 2000-07-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
BR0008403A (pt) 1999-02-23 2002-01-29 Merck & Co Inc Formulação farmacêutica para administração oral
DE60033028T2 (de) 1999-04-23 2007-11-15 Takeda Pharmaceutical Co. Ltd. 5-pyridyl-1,3-azol-derivate, verfahren zu ihrer herstellung und ihre verwendung
ATE284205T1 (de) 1999-10-01 2004-12-15 Natco Pharma Ltd Magensaftresistente gelartige weichkapsel
IN192188B (https=) 2000-06-16 2004-03-13 Ranbaxy Lab Ltd
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
AU2001289438A1 (en) * 2000-09-22 2002-04-02 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
PL371133A1 (en) 2001-12-20 2005-06-13 Pharmacia Corporation Pharmaceutical suspension for oral administration
EP1490025B1 (en) 2002-03-20 2008-02-13 Elan Pharma International Limited Nanoparticulate compositions of map kinase inhibitors
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
AU2003251661A1 (en) 2002-08-06 2004-02-25 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
TW200412948A (en) 2002-08-23 2004-08-01 Ionix Pharmaceuticals Ltd Therapeutic compounds
JP2004099442A (ja) 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
EP1546141A1 (en) 2002-09-06 2005-06-29 Vertex Pharmaceuticals Incorporated Isoxazoles and their use in the treatment of ischemic diseases
MXPA05006670A (es) 2002-12-18 2005-10-19 Algorx Pharmaceuticals Inc Administracion de capsaicinoides.
US7550480B2 (en) 2003-02-14 2009-06-23 Smithkline Beecham Corporation Compounds
EP1601672B1 (en) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
JPWO2004073692A1 (ja) 2003-02-18 2006-06-01 山下　伸二 難水溶性薬物のハードカプセル剤
JP2005013938A (ja) 2003-06-27 2005-01-20 Canon Inc 脱色装置及び方法
US20060151899A1 (en) 2003-08-06 2006-07-13 Akira Kato Process for producing drug ultramicroparticle and apparatus therefor
JP5096658B2 (ja) 2003-10-06 2012-12-12 株式会社三協 生物学的利用能を向上させたソフトカプセル
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
WO2005085249A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
MXPA06012758A (es) * 2004-05-04 2007-01-16 Hormos Medical Ltd Novedosas formulaciones orales de ospemifeno.
US7939536B2 (en) 2004-12-28 2011-05-10 Aska Pharmaceutical Co., Ltd. Pyrimidinylisoxazole derivatives
JP2007039408A (ja) * 2005-08-05 2007-02-15 Unitec Foods Co Ltd 微粉化クレアチンとその製造方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103655512A (zh) * 2013-12-12 2014-03-26 海南海力制药有限公司 一种硝酸芬替康唑阴道软胶囊及其制备方法
CN103655512B (zh) * 2013-12-12 2015-05-20 海南海力制药有限公司 一种硝酸芬替康唑阴道软胶囊及其制备方法

Also Published As

Publication number Publication date
KR20090117894A (ko) 2009-11-13
WO2008099615A1 (ja) 2008-08-21
US20100092565A1 (en) 2010-04-15
EP2123255A4 (en) 2010-06-02
JPWO2008099615A1 (ja) 2010-05-27
EP2123255B1 (en) 2013-05-15
JP2010120974A (ja) 2010-06-03
US8309138B2 (en) 2012-11-13
AU2008215659A1 (en) 2008-08-21
CA2677842C (en) 2014-09-16
JP4588791B2 (ja) 2010-12-01
EP2123255A1 (en) 2009-11-25
CA2677842A1 (en) 2008-08-21
KR101434706B1 (ko) 2014-08-26
ES2423929T3 (es) 2013-09-25
AU2008215659B2 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
Chaudhari et al. Application of surfactants in solid dispersion technology for improving solubility of poorly water soluble drugs
CN101610754A (zh) 含有微粒油性混悬液的药物组合物
ES2326085T3 (es) Composiciones que comprenden meloxicam en nanoparticulas.
CN106061261B (zh) 治疗化合物的结晶形式及其用途
CN112770727A (zh) 大麻素的缓速释放配方
KR101824831B1 (ko) 신규 멜록시캄 제제
TW200821298A (en) Pharmaceutical compositions
JP7525674B2 (ja) デュタステリドを含む固形製剤およびその製造方法
CN104428001A (zh) Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
CN109803684B (zh) 用于治疗肝细胞癌的组合疗法
Liu Nanocrystal formulation for poorly soluble drugs
JP5021887B2 (ja) アゼチジン誘導体に基づく医薬組成物
US9040091B2 (en) Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
BR112019014712A2 (pt) Tratamento médio que compreende a administração entérica de edaravona
WO2011074660A1 (ja) 溶出安定性製剤
US20160015691A1 (en) Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth
JPWO2006073154A1 (ja) 医薬組成物及びその製造方法
TWI597063B (zh) 藥物組成物及其製備方法
KR101476096B1 (ko) 용해도가 향상된 쎄레콕시브의 약제학적 조성물
ES2785398T3 (es) Composición farmacéutica que comprende Aripiprazol o sal del mismo
Dhiman et al. Revolutionizing Drug Delivery: The Promise of Self-emulsifying Systems in Overcoming Bioavailability Challenges
BR112019016400A2 (pt) composições de complexos de gálio (iii) para administração oral
Azad et al. Recent Advances in Delivering Strategies of Domperidone: Challenges and Opportunities
Ahmad et al. Oral Administration of Cancer Chemotherapeutics Exploiting Self-Nanoemulsifying Drug Delivery System: Recent Progress and Application
JP5106119B2 (ja) シクロオキシゲナーゼ−２阻害剤を含む経口投与用の薬剤、およびその調製方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20091223